GlucoTrack, Inc.
GCTK
NASDAQ·Healthcare·Medical - Devices·Mkt cap $2.8M
$3.39
▼ -3.97%
P/E
—
Mkt Cap
$2.8M
52-Wk Range
$3.29–$212.10
52-Week Range
$3.29 - $212.10
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 95.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary non-invasive glucose monitoring technology
- Patent-protected intellectual property
- First-mover advantage in painless glucose monitoring
- Strong regulatory clearance and certifications
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
No forward estimates available
Rising global diabetes prevalence and diagnosis rates
Value
Valuation data unavailable
Momentum
Falling
-64.6% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying GCTK right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
AUG 14, 2026
Most recent quarter reported revenue of $0. Reported EPS of $0.76.
Reported EPS · last 4Q
0 of 1 beats
Q3 26
—
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How GCTK stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related